Brian Skorney
Stock Analyst at Baird
(3.42)
# 966
Out of 4,761 analysts
101
Total ratings
41.89%
Success rate
7.09%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $940 → $759 | $700.33 | +8.38% | 13 | Feb 5, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $46 | $14.01 | +228.34% | 1 | Dec 13, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $11.30 | +165.49% | 1 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Reiterates: Outperform | $72 | $46.13 | +56.08% | 2 | Dec 2, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.53 | +843.40% | 4 | Nov 29, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $26 → $20 | $8.03 | +149.07% | 6 | Nov 26, 2024 | |
| BIIB Biogen | Maintains: Outperform | $294 → $300 | $140.64 | +113.31% | 16 | Nov 15, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $44 → $50 | $52.45 | -4.67% | 4 | Nov 13, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $200 → $193 | $106.28 | +81.60% | 9 | Nov 7, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $80 → $95 | $109.95 | -13.60% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.17 | +383.56% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $3.19 | +213.48% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $303.01 | -29.05% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $58 → $60 | $36.91 | +62.56% | 2 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $120.69 | +49.14% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $3.89 | +619.79% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $37.46 | +65.51% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $7.27 | +436.45% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $39.73 | +58.57% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $484.24 | -32.88% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $21.27 | -52.99% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.93 | +9,115.02% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.22 | +42.18% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $3.10 | +9,577.42% | 3 | May 7, 2018 |
Regeneron Pharmaceuticals
Feb 5, 2025
Maintains: Neutral
Price Target: $940 → $759
Current: $700.33
Upside: +8.38%
Dyne Therapeutics
Dec 13, 2024
Initiates: Outperform
Price Target: $46
Current: $14.01
Upside: +228.34%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $11.30
Upside: +165.49%
Soleno Therapeutics
Dec 2, 2024
Reiterates: Outperform
Price Target: $72
Current: $46.13
Upside: +56.08%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.53
Upside: +843.40%
Enanta Pharmaceuticals
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $8.03
Upside: +149.07%
Biogen
Nov 15, 2024
Maintains: Outperform
Price Target: $294 → $300
Current: $140.64
Upside: +113.31%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Outperform
Price Target: $44 → $50
Current: $52.45
Upside: -4.67%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $200 → $193
Current: $106.28
Upside: +81.60%
Gilead Sciences
Nov 7, 2024
Maintains: Neutral
Price Target: $80 → $95
Current: $109.95
Upside: -13.60%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $5.17
Upside: +383.56%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $3.19
Upside: +213.48%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $303.01
Upside: -29.05%
Sep 23, 2024
Maintains: Outperform
Price Target: $58 → $60
Current: $36.91
Upside: +62.56%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $120.69
Upside: +49.14%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $3.89
Upside: +619.79%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $37.46
Upside: +65.51%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $7.27
Upside: +436.45%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $39.73
Upside: +58.57%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $484.24
Upside: -32.88%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $21.27
Upside: -52.99%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.93
Upside: +9,115.02%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.22
Upside: +42.18%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $3.10
Upside: +9,577.42%